Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Radiant Research Inc

Neither a doctor nor a teaching hospital

Research payments

$1,120,929

358 payments

Through program year 2025, Radiant Research Inc is reported as receiving $1,120,929 in research payments, across 358 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,381 3
2024 Research $15,092 4
2023 Research $9,862 5
2022 Research $6,395 10
2021 Research $46,794 43
2020 Research $90,822 59
2019 Research $950,582 234

Breakdown

Who paid Research payments · program years 2019–2025
  1. Allergan Inc. $365,504 75 payments
  2. Kowa Research Institute, Inc. $310,853 110 payments
  3. Eli Lilly and Company $160,953 80 payments
  4. AbbVie, Inc. $87,301 12 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $63,872 14 payments
  6. Endo Pharmaceuticals Inc. $35,347 13 payments
  7. Abbott Laboratories $30,073 4 payments
  8. Sunovion Pharmaceuticals Inc. $19,095 24 payments
  9. Otsuka Pharmaceutical Development & Commercialization, Inc. $14,492 3 payments
  10. Ucb SA $7,438 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. K-877-302 $300,641 95 payments
  2. A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Longterm Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $153,097 34 payments
  3. A Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in A Dose-Reduction Paradigm in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current $152,517 23 payments
  4. M16-766 $87,301 12 payments
  5. A Double-Blind, Placebo-Controlled, Randomized Withdrawal,Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in A Dose-Reduction Paradigm in the Prevention of Relapse in Patients With Schizophrenia $53,458 16 payments
  6. Lot-to-lot Consistency of 3 Lots of TDV in Non-Endemic Countryies for Dengue $40,777 9 payments
  7. A Phase 3B, Open-Label, Long-Term Study to Evaluate the Safety and Temporal Pattern of Response of En3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy $31,889 11 payments
  8. A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of Ly3314814 in Mild Alzheimers Disease Dementia $26,712 2 payments
  9. Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $24,648 10 payments
  10. A Randomized, Double-Blind, Placebo-Controlled, Phase 4, Relapse Prevention Study Evaluating the Efficacy and Safety of Vortioxetine 5, 10 and 20 mg in Adults With Major Depressive Disorder $23,095 5 payments
What the money was spent on Research payments · program years 2019–2025
  1. Other $63,872 14 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record